

Daniel Langer

## **18.1 Rationale and Background**


Notably, the most prominent exercise-limiting symptom of patients with chronic respiratory conditions is dyspnea [1] which is associated with avoidance of activities, with subsequent deconditioning [2]. Dyspnea is defined as an uncomfortable sensation of breathing [3]. The respiratory muscles play a key role in the perception of dyspnea [4–6] and in limiting exercise tolerance in patients [6–8]. Respiratory muscle dysfunction is moreover frequently observed in patients with chronic lung diseases [9, 10]. Several factors contribute to respiratory muscle dysfunction in these patients, including lung hyperinflation, hypoxemia, hypercapnia, inflammation, malnutrition, long-term use of corticosteroids, physical inactivity, and changes

in the fiber type distribution in the respiratory muscles (Fig. 18.6–8, 11–13]. Lung hyperinflation is a major cause of respiratory muscle dysfunction in patients with obstructive lung disease since it places the inspiratory muscles at a mechanical disadvantage. In addition, many shared risk factors contribute to both respiratory and limb muscle dysfunction (Fig. 18.9]. Lung hyperinflation causes shortening of the diaphragm, so that the muscle is able to generate less pressure during contraction [14]. At the same time, the inspiratory muscles have to overcome higher elastic and resistive loads, especially during exercise. There are compensatory mechanisms present by which the respiratory muscles of patients adapt to these mechanical disadvantages and increased chronic loading (Fig. 18.10]. With these adaptations the diaphragm partially preserves its ability to generate pressure during normal breathing despite its shortened operating length and becomes more fatigue resistant [2, 15–17]. In response to chronic hyperinflation, for example, the inspiratory muscles adapt by shortening of sarcomeres, such that, at a given lung volume, pressure generation is well preserved or even increased (Fig. 18.11, 18]. This is however not effective to adapt to acute changes induced by dynamic hyperinflation during physical activities. Other adaptations (e.g., changes in fiber type distribution) are generally believed to be responses to chronic overload (Fig. 18.12].

D. Langer  
 KU Leuven—University of Leuven, Faculty of  
 Kinesiology and Rehabilitation Sciences,  
 Leuven, Belgium

Laboratory of Respiratory Diseases,  
 KU Leuven—Campus Gasthuisberg—O&N1,  
 Herestraat 49 Box 706, B-3000 Leuven, Belgium

Respiratory Rehabilitation and Respiratory Division,  
 University Hospitals Leuven, Leuven, Belgium  
 e-mail: [daniel.langer@faber.kuleuven.be](mailto:daniel.langer@faber.kuleuven.be)



**Fig. 18.1** Respiratory muscle adaptations in patients with COPD

AU2  
AU9

In the respiratory muscles, etiologic factors such as alterations in the chest geometry and mechanical overload can to some extent counteract (training effect, right tray of the scales) the deleterious effects of the other etiologic factors of a more systematic nature (left tray of the scales). The factors mentioned on the left tray of the scales also contribute to limb muscle dysfunction in these patients. (b) In the respiratory muscles, several structural adaptation have beneficial effects (adaptive mechanisms, right tray of the scales), which partly counteract the deleterious effects of the other biological mechanisms (left tray of the scales). Reproduced with permission from: Arch Bronconeumol 2015;51:384–95 – Vol. 51(8). doi: [10.1016/j.arbr.2015.04.027](https://doi.org/10.1016/j.arbr.2015.04.027) Recommendations of SEPAR Guidelines for the Evaluation and Treatment of Muscle Dysfunction in Patients With Chronic Obstructive Pulmonary Disease.

The compensatory mechanisms present are believed to not fully compensate for the deleterious effects on the respiratory muscles, especially in patients with severe COPD (Fig. 18.1) [19]. Moreover they can quickly become overwhelmed when the ventilation requirements are acutely increased during physical activities. Not only are the respiratory muscles not able to adapt to length changes brought about by this acute hyperinflation but they are also not trained to operate at shorter lengths and higher contraction velocities due to avoidance of activities. The resulting imbalances between load and capacity of the

respiratory muscles are closely related to the perception of dyspnea in patients with lung disease especially during exercise (Fig. 18.2) [20].

While highlighting these specific mechanisms that contribute to exercise limitation it is however also important to stress that in patients with lung disease, other factors besides dyspnea, mechanical constraints, and ventilatory limitation are relevant. These factors include peripheral muscle dysfunction and inappropriate increase in energy demands due to recruitment of abdominal muscles [21, 22].

Several pharmacological and non-pharmacological treatment options are available to enable the respiratory muscles of patients to better cope with these high loads, either by attempting to decrease the load on the respiratory muscles (e.g., bronchodilation or ventilatory support) or by improving respiratory muscle function [23, 24]. IMT has been frequently applied in the last decades to improve inspiratory muscle function (both pressure generating capacity and endurance) in patients in order to reduce dyspnea and improve exercise capacity [25].

## 18.2 Evidence

Different methods for respiratory muscle training have been applied in the past during pulmonary rehabilitation (PR). These include methods that predominantly aim to increase muscle strength, such as targeted resistive breathing [26], and

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110


111

112

113

114

**Fig. 18.2** The ventilatory load-capacity balance and dyspnea in COPD (Reprinted with permission of the American Thoracic Society. Copyright© 2016 American Thoracic Society. Jolley CJ, Moxham J. 2016. Dyspnea Intensity: A Patient-reported Measure of Respiratory Drive and Disease Severity. *Am J Respir Crit Care Med*; 193(3):236–8



115 threshold loading [27], as well as methods that  
 116 predominantly aim at increasing muscle endurance,  
 117 such as isocapnic hyperpnea [28]. Recently  
 118 a hybrid between threshold loading and targeted  
 119 resistive loading (tapered flow resistive loading)  
 120 has gained more popularity [29]. We will discuss  
 121 the different methodologies in more detail in the  
 122 following paragraph. In general, the role of the  
 123 respiratory muscles in respiratory rehabilitation  
 124 remains controversial, even after more than  
 125 40 years of research [30]. The available evidence  
 126 in patients with COPD will be reviewed first.  
 127 After that the (more limited) evidence available  
 128 in other obstructive and nonobstructive respira-  
 129 tory disorders will also be discussed.

### 130 18.2.1 COPD

131 In terms of the demonstrated functional responses  
 132 to IMT, three meta-analyses have been of key  
 133 importance in patients with COPD [25, 31, 32].  
 134 The first meta-analysis by Smith et al. from 1992  
 135 has been very influential and has shaped the per-  
 136 ception of effectiveness of this intervention for sev-  
 137 eral years. The review included 17 randomized  
 138 trials [32]. Across included studies small and  
 139 non-significant effect sizes were reported: maxi-  
 140 mal inspiratory mouth pressure (Pimax): 0.12,  
 141  $p = 0.38$ ; inspiratory muscle endurance 0.21,  
 142  $p = 0.14$ ; exercise capacity  $-0.01$ ,  $p = 0.43$ ; func-

143 tional exercise capacity 0.20,  $p = 0.15$ ; and func-  
 144 tional status 0.06,  $p = 0.72$ . This meta-analysis,  
 145 however, took all studies into account, regardless  
 146 of whether or not training load was controlled. A  
 147 subgroup analysis indicated more consistent  
 148 improvements in inspiratory muscle strength and  
 149 endurance in those studies where targeted resis-  
 150 tive loading with adequate loads was applied  
 151 [32].

152 A second meta-analysis by Lötters et al. from  
 153 2002 more carefully selected only randomized  
 154 controlled studies in which training load was ade-  
 155 quately controlled during training, restricting  
 156 intake to 15 studies employing loads of at least  
 157 30% of Pimax in comparison with either sham or  
 158 no IMT intervention [31]. This meta-analysis was  
 159 subsequently updated by Gosselink et al. in 2011  
 160 to include 32 randomized controlled trials (total  
 161  $n = 830$ ; IMT:  $n = 430$ , control:  $n = 400$ ) based on  
 162 similar selection criteria [25]. On the basis of a  
 163 methodological framework, a critical review was  
 164 performed, and summary effect sizes were calcu-  
 165 lated by applying both fixed and random effect  
 166 models. This approach more clearly demonstrated  
 167 the effects of IMT. Indeed, both IMT alone and  
 168 IMT combined with general exercise recondition-  
 169 ing significantly increased inspiratory muscle  
 170 function (strength and endurance). Dyspnea symp-  
 171 toms were also reduced. A trend for improved  
 172 functional exercise capacity after IMT which did  
 173 not reach statistical significance in the 2002

174 meta-analysis was found to be statistically signifi- 202  
 175 cant after inclusion of more studies in the 2011 203  
 176 meta-analysis [25]. An overview of overall results 204  
 177 from the 2011 meta-analysis including effect sizes 205  
 178 and transformation of observed effects into natural 206  
 179 units improvements is provided in Table 18.1. 207  
 180 IMT studied in addition to a general exercise pro- 208  
 181 gram improved P<sub>imax</sub> significantly, while addi- 209  
 182 tional improvements in functional exercise 210  
 183 capacity could not be demonstrated. However, 211  
 184 subgroup analysis in studies combining IMT with 212  
 185 exercise training demonstrated that patients with 213  
 186 inspiratory muscle weakness improved signifi- 214  
 187 cantly more than patients served muscle func- 215  
 188 tion [25]. This observation may be of more general 216  
 189 interest. Indeed, so far, most studies in this area 217  
 190 have included all COPD patients, instead of select- 218  
 191 ing COPD patients whose outcomes are more 219  
 192 likely related to inspiratory muscle function. Some 220  
 193 phenotypes defined by stage of COPD, presence 221  
 194 of inspiratory muscle weakness, degree of hyper- 222  
 195 inflation, severity of dyspnea, level of exercise 223  
 196 intolerance, and reduced health status may be 224  
 197 other important determinants of the response to 225  
 198 IMT [30]. Due to absence of conclusive data it is 226  
 199 however still unclear how to best identify patients 227  
 200 that are most likely to benefit from the 228  
 201 intervention. 229

A word of caution is required in relation to the 202  
 interpretation of results from these meta-analyses. 203  
 Pooling of results is associated with a number of 204  
 methodological problems. These include differ- 205  
 ences in populations, study design, training inter- 206  
 ventions, duration of trials, collection of data, drop 207  
 out, and other inconsistencies between the studies. 208  
 A large prospective randomized study is currently 209  
 ongoing which addresses most of these issues and 210  
 should facilitate interpretation of outcomes [33]. 211

Most current guidelines are not undisputedly 212  
 positive on the application of IMT during 213  
 PR. The most recent ERS/ATS statement on 214  
 respiratory rehabilitation acknowledges that 215  
 “current evidence indicates that IMT used in 216  
 isolation does confer benefits across several out- 217  
 come areas.” [34] It stresses however also the 218  
 lack of proven added benefit of this intervention 219  
 as an adjunct to general exercise training in 220  
 COPD. Based on this (lack of convincing) data 221  
 the recommendation was formulated that “IMT 222  
 might be useful when added to whole-body 223  
 exercise training in individuals with marked 224  
 inspiratory muscle weakness” [34]. In this con- 225  
 text it is worth mentioning that many other add- 226  
 on treatments to general exercise training, 227  
 including, for example, lower limb strength 228  
 training, have also failed to result in additional 229

**Table 18.1** Overall results of the meta-analysis (Gosselink et al. [25])

Outcome	SES	95% CI	p-Value	Natural units
$P_{1,max}$	0.73	0.53 to 0.93	0.001	+13 cmH <sub>2</sub> O
RMET	1.05	0.62 to 1.49	0.001	+261 s
ITL	0.98	0.72 to 1.25	0.001	+13 cmH <sub>2</sub> O
MVV	0.23	-0.27 to 0.72	0.373	+3 L min <sup>-1</sup>
Functional exercise capacity	0.28	0.12 to 0.44	0.001	6MWD: +32 m
Endurance exercise capacity	0.72	-0.12 to 1.55	0.087	+198 s
$V_{I,max}$ L min <sup>-1</sup>	-0.13	-0.38 to 0.11	0.293	-0.04 L min <sup>-1</sup>
$V_{O_{2,max}}$ mL min <sup>-1</sup> kg <sup>-1</sup>	0.3	-0.02 to 0.63	0.067	+1.3 mL min <sup>-1</sup> kg <sup>-1</sup>
$V_{E,max}$	-0.04	-0.3 to 0.2	0.696	-0.7 L min <sup>-1</sup>
$W_{max}$	0.07	-0.16 to 0.3	0.562	+1.7 W
Dyspnoea Borg score	-0.45	-0.66 to -0.24	0.001	-0.9
Dyspnoea TDI	1.58	0.86 to 2.3	0.001	+2.8
Dyspnoea CRQ-Dyspnoea	0.34	-0.03 to 0.71	0.068	+1.1

11.16 SES summary effect size,  $P_{1,max}$  maximal inspiratory mouth pressure, *RMET* respiratory muscle endurance test, *ITL*  
 11.17 incremental threshold loading, *MVV* maximal voluntary ventilation,  $V_{O_{2,max}}$  maximal oxygen uptake,  $V_{E,max}$  maximal  
 11.18 minute ventilation,  $W_{max}$  maximal power output, *TDI* transition dyspnoea index, *CRQ* chronic respiratory  
 11.19 questionnaire

improvements in functional exercise capacity or quality of life in similar study designs. This evidence has recently been summarized in a systematic literature review [35]. Quite in contrast to the similarities in available data the addition of lower limb strength training to PR is however generally encouraged [34]. It has been argued that priority during PR programs in the context of limited resources and time available should be given to the most effective components of the program (i.e., general exercise training) instead of spending too much time on add-on interventions with unproven additional benefit [36]. In the following paragraph innovations in training methods and equipment will be reviewed that might contribute to facilitate implementing well-controlled respiratory muscle training as add-on interventions during PR. Based on the currently available evidence, the recent GOLD guidelines acknowledge the potential benefits of respiratory muscle training especially when combined with general exercise training with evidence level C [37]. To provide additional evidence in support of more clinically relevant effects of IMT as an add-on treatment to PR carefully designed studies implemented in highly selective patient groups using the most appropriate outcomes will be needed [35]. A challenge in conducting these studies will be the considerable sample sizes needed to demonstrate additional effects on functional exercise capacity or quality of life on top of the large effects that will already be obtained in the active control groups (patients participating in general exercise training). It will therefore be necessary to selectively identify and include patients in these studies who are not able to benefit to the fullest from a standard rehabilitation program.

Two additional lines of evidence further support the beneficial effect on inspiratory muscle function with properly controlled IMT. First, Gayan-Ramirez et al. demonstrated in an elegantly designed animal model in rats that intermittent resistive loading resulted in type II fiber hypertrophy in the diaphragm [38]. Second, Ramirez-Sarmiento et al. observed an increase in external intercostal muscle fiber cross-sectional area and an increase in proportion of type I fibers

in COPD patients following 5 week of resistive loading [39]. These studies both demonstrated that structural remodeling of the inspiratory muscles occurred with IMT. In any event, an effect of IMT on dyspnea is expected on the basis of the pathophysiological observations made by Redline and colleagues [40]. They demonstrated in normal subjects that the sensation of respiratory force was related to the fraction of Pimax used in breathing maneuvers. Hence, increasing Pimax would be expected to reduce the sensation of respiratory force. Whether these concepts truly apply to patients with COPD has not been convincingly demonstrated. Recent data collected in patients with COPD has provided initial evidence on possible beneficial effects on breathing pattern and operating lung volumes during exercise in response to IMT [41, 42]. The adoption of a more efficient breathing pattern in combination with reduced neural activation of the respiratory muscles should improve neuromechanical coupling and might be related to improvements in exertional breathlessness in these patients in response to IMT [43]. More research on possible mechanisms explaining the reduction in dyspnea after IMT and on identifying the most suitable candidates for this intervention is warranted in the coming years.

The general conclusion for patients with COPD appears to be that, if properly applied, IMT improves inspiratory muscle function. Particularly in patients with compromised inspiratory muscle function these improvements also seem to translate into functional and symptomatic benefits. Based on clinical experience and the available evidence it can therefore at this moment be recommended to select motivated patients with impaired respiratory muscle function in whom dyspnea is an important contributor to activity limitation to participate in add-on IMT interventions during their PR program.

## 18.2.2 IMT in Other Obstructive Lung Diseases

The consequences of expiratory flow limitation and dynamic hyperinflation on the load/capacity bal-

323 ance of the respiratory muscles in patients with  
 324 other obstructive lung diseases (e.g., asthma, cystic  
 325 fibrosis, or non-CF bronchiectasis) are similar to  
 326 those observed in patients with COPD. Differences  
 327 exist concerning the prevalence and severity of  
 328 respiratory muscle dysfunction between those  
 329 patient populations. Volume and quality of available  
 330 data are moreover not comparable to the literature  
 331 available in COPD. In the following paragraphs the  
 332 available evidence and applied training protocols in  
 333 these patient groups will be summarized.

## 334 18.2 Asthma

335 Improving respiratory muscle function in these  
 336 patients could help to prevent overload of respira-  
 337 tory muscles during asthma attacks and should  
 338 relieve acute symptoms of breathlessness due to  
 339 dynamic hyperinflation. Respiratory muscle func-  
 340 tion in non-steroid dependent asthmatics however  
 341 seems to be on average less impaired than in  
 342 patients with COPD [44–47]. The available data in  
 343 terms of randomized controlled trials is less com-  
 344 prehensive and results are less conclusive than in  
 345 patients with COPD. The results of 5 randomized  
 346 controlled trials (total  $n = 113$ ) were summarized  
 347 in a 2013 Cochrane meta-analysis [48]. Except for  
 348 a statistically significant improvement in Pimax no  
 349 significant improvements in symptoms or depen-  
 350 dency on medical treatment could be demon-  
 351 strated. All studies applied either flow resistive or  
 352 mechanical threshold loading with controlled  
 353 training intensities (40–60%  $P_{i,max}$ ). Vast differ-  
 354 ences were however present concerning training  
 355 frequency and duration of IMT programs. With  
 356 exception of a study by Sampaio and colleagues  
 357 all subjects were categorized as having mild to  
 358 moderate persisting asthma [48]. A further study  
 359 by Turner and colleagues (2011) which was not  
 360 included in the meta-analysis investigated the  
 361 effects of 6 weeks of mechanical threshold loading  
 362 IMT in patients with mild to moderate persisting  
 363 asthma [49]. Patients trained twice daily at 50%  
 364 of their  $P_{i,max}$  ( $n = 7$ ) or at 15%  $P_{i,max}$  (sham-control-  
 365 group,  $n = 8$ ). The IMT group achieved significant  
 366 increases in  $P_{i,max}$  (+28%), endurance cycling time  
 367 (+16%), and symptoms of dyspnea on exertion  
 368 (–16%). No significant changes were observed in

the control group. Due to the small number of par- 369  
 ticipants, the between group comparisons did 370  
 however not reach statistical significance. Larger 371  
 (multicenter) studies performed in patients with 372  
 more severe and persisting forms of asthma are 373  
 needed to find out whether IMT can result in func- 374  
 tional and symptomatic benefits in these patients. 375

## 18.2 Cystic Fibrosis

In analogy to patients with COPD ventilatory 377  
 needs during exercise are increased for a given 378  
 workrate in these patients. Airway resistance, 379  
 increases in intrinsic positive end expiratory 380  
 pressure, and decreased lung compliance with 381  
 increasing breathing frequencies increase the 382  
 load on these muscles [50]. Moreover in patients 383  
 with CF insufficient uptake of nutrients in combi- 384  
 nation with a persisting catabolic metabolism due 385  
 to chronic inflammation can contribute to periph- 386  
 eral and respiratory muscle dysfunction [51, 52]. 387  
 In analogy to patients with COPD the higher load 388  
 on the respiratory muscles is thus combined with 389  
 a reduced capacity [51, 52]. 390

Despite this solid physiological rationale for 391  
 the application of IMT in these patients, the avail- 392  
 able database is limited. Only one further study 393  
 has investigated the effects of IMT in patients 394  
 with CF following a meta-analysis by Reid and 395  
 colleagues performed in 2008 [50, 53]. Since this 396  
 study investigated the effects of a combined gen- 397  
 eral exercise and IMT intervention with a control 398  
 intervention, it is however less relevant in the 399  
 current context [54]. In neither of the two ran- 400  
 domized controlled studies that were included in 401  
 the meta-analysis (total  $n = 36$ ) improvements in 402  
 symptoms or quality of life were observed [55, 403  
 56]. Further studies would therefore be needed to 404  
 find out whether IMT can result in symptomatic 405  
 benefits in patients cystic fibrosis. 406

## 18.2.5 Non-CF Bronchiectasis

In analogy with COPD patients Koulouris and col- 408  
 leagues demonstrated a relationship between nega- 409  
 tive consequences of expiratory flow limitation on 410  
 loading of the respiratory muscles, dyspnea, and 411

412 reductions in exercise capacity [57]. Moran and col- 458  
 413 leagues observed reductions in respiratory muscle 459  
 414 strength in most patients with NCFB [58]. Owing to 460  
 415 these similarities in pathophysiology between 461  
 416 COPD and NCFB comparable rehabilitative strate- 462  
 417 gies, including respiratory muscle training, are rec- 463  
 418 ommended for both patient groups [59]. The 464  
 419 available evidence is however, similar to the situa- 465  
 420 tion in asthma and patients with cystic fibrosis, far 466  
 421 less comprehensive than in patients with COPD. 467

422 Only two studies have so far investigated the 468  
 423 effects of IMT in NCFB. Newall and colleagues 469  
 424 compared general exercise training in combina- 470  
 425 tion with either IMT (twice daily training for 471  
 426 15 min each, starting at 30%  $P_{i,max}$  weekly 472  
 427 increase of resistance of ~5%,  $n = 12$ ) or “Sham” 473  
 428 MTL-Training (fixed resistance of 7cmH<sub>2</sub>O, 474  
 429  $n = 11$ ) with a control group (usual care,  $n = 9$ ) 475  
 430 [60]. Patients were not selected for having respi- 476  
 431 ratory muscle weakness. The larger increase in 477  
 432 exercise capacity and respiratory muscle function 478  
 433 in the combined exercise training/IMT group in 479  
 434 comparison with exercise training /Sham-IMT 480  
 435 did not reach statistical significance due to small 481  
 436 group sizes. Only differences of both groups with 482  
 437 the usual care group could be demonstrated. Liaw 483  
 438 et al. investigated the effects of “stand-alone” 484  
 439 IMT in comparison with a control group (“usual 485  
 440 care”) [61]. Patient characteristics and training 486  
 441 program were very similar to the study of Newall 487  
 442 and colleagues. Statistically significant improve- 488  
 443 ments in respiratory muscle function were 489  
 444 observed. Due to the limited group sizes (both 490  
 445  $n = 13$ ) clinically relevant larger increase in 491  
 446 6-min walking distance (42 m) did however not 492  
 447 reach statistical significance. These preliminary 493  
 448 results found in very small studies are promising. 494  
 449 Larger studies will however be needed to investi- 495  
 450 gate whether IMT can truly result in functional 496  
 451 benefits in these patients. 497  
 498  
 499  
 500  
 501  
 502

## 18.1 Restrictive Respiratory Disorders: Interstitial Lung Disease

455 Patients with ILD have to cope with higher elastic 500  
 456 loads during breathing. In the ILD group, respira- 501  
 457 tory muscles, and in particular the diaphragm, are 502

458 however less disadvantaged compared with 459  
 460 patients with COPD, probably owing to the rela- 460  
 461 tively lower EELV and more favorable length–ten- 461  
 462 sion characteristics [62–64]. Accordingly, resting 462  
 463 MIP and MVV are greater, together with a greater 463  
 464 diaphragmatic contribution to increasing ventila- 464  
 465 tion [63]. Specific studies on the effects of IMT in 465  
 466 ILD are currently not available. Only the combina- 466  
 467 tion of IMT and general exercise training in com- 467  
 468 parison to a control group has been studied so far 468  
 469 [65]. There are however indications that improve- 469  
 470 ments in peak tidal volumes after general exercise 470  
 471 training programs in patients with ILD are signifi- 471  
 472 cantly correlated ( $r = 0.78$ ,  $p = 0.001$ ) with 472  
 473 improvements in  $\dot{V}O_{2peak}$  values [66]. This has 473  
 474 been attributed to the repetitive stimulus of high 474  
 475 ventilatory demand during exercise sessions in 475  
 476 combination with chest expansion during deep- 476  
 477 breathing exercises and stretching of the thoracic 477  
 478 muscles. This is consistent with a review paper 478  
 479 that suggested a beneficial effect of thoracic 479  
 480 expansion and stretching on pulmonary restriction 480  
 481 in IPF [67]. It is likely that specific inspiratory 481  
 482 muscle resistance will have a larger impact on 482  
 483 these variables than general exercise training or 483  
 484 normocapnic hyperpnea. It might therefore be 484  
 485 worthwhile to study additional effects of IMT in 485  
 486 this population despite the relatively well-pre- 486  
 487 served respiratory muscle function. 486

## 18.3 Implementation of IMT in Clinical Practice

### 18.3.1 Patient Assessment

490 Assessment prior to IMT requires measurements 490  
 491 of inspiratory muscle function (strength and 491  
 492 endurance) in addition to outcome measures such 492  
 493 as dyspnea, exercise capacity, and HRQOL. Both 493  
 494 maximum static inspiratory pressure that a sub- 494  
 495 ject can generate at the mouth (P<sub>imax</sub>) and mus- 495  
 496 cle endurance are often measured in specialized 496  
 497 respiratory medicine laboratories [54]. Small 497  
 498 handheld devices have however become com- 498  
 499 mercially available for these purposes [68]. These 499  
 500 devices have made it easier to perform these tests 500  
 501 in less specialized centers or even in the home 501  
 502 setting. 502

### 18.3.2 Strength

Measurement of P<sub>i,max</sub> is a simple way to measure inspiratory muscle strength in a clinical setting. Practice attempts are required because P<sub>i,max</sub> improves significantly with familiarization [69]. To standardize the measurement, it has been recommended to measure P<sub>i,max</sub> at or close to RV [54]. The test should be performed by a trained operator who should strongly encourage subjects to make maximum inspiratory efforts. Subjects are normally seated and noseclips are required. Because this is an unfamiliar maneuver, careful instruction and encouraged motivation are essential. Subjects also often need coaching to prevent air leaks around the mouthpiece. Once the operator is satisfied, the maximum value of three maneuvers that vary by less than 10% is recorded. The system requires a small leak to prevent glottic closure during the P<sub>i,max</sub> maneuver. The inspiratory pressure should be maintained, ideally for at least 2 s, so that the maximum pressure sustained for 1 s can be recorded. The peak pressure is on average higher than the 1 s of sustained pressure but is believed to be less reproducible [54, 70]. The pressure transducers should ideally be connected with a screen in order to display pressure-time curves and computations of the 1-sec plateau pressure. Flanged mouthpieces are readily available in pulmonary function laboratories and although they give values somewhat lower than those obtained with rubber tube mouthpieces, the differences are not usually considered important in a clinical setting [54]. In spite of many assumptions, the recorded pressure is believed to usefully reflect global respiratory muscle strength for clinical evaluation [54]. Sources of variation include type of mouthpiece, presence of a small leak, evalu-

ated pressure (peak or plateau), number of trials performed, and lung volume from which the test is performed. Increases in P<sub>i,max</sub> have been found in response to specific training in comparison to control groups which indicates that the test is responsive to IMT interventions [25]. Twenty-two studies have been identified that provide reference values for MIP measurements collected in accordance with the abovementioned ATS/ERS measurement guidelines [71]. These data have recently been synthesized to provide age-specific reference values (Table 18.2) [71].

Comparison of P<sub>i,max</sub> before and after IMT allows clinicians to determine whether the training load was adequate to induce a training-related improvement in inspiratory muscle strength. A lack of change in P<sub>i,max</sub> is likely to indicate inadequate training loads. Improvements in muscle endurance have also been demonstrated after high flow, low pressure endurance training methods (e.g., isocapnic hyperpnea, for description of technique see next paragraph). There are however indications that higher training resistances tolerated during training result in larger improvements in endurance parameters [29].

### 18.3.3 Endurance

External loading protocols are frequently used to measure respiratory muscle endurance. These tests are characterized by the imposition of either incremental or constant submaximal inspiratory loads, sustained until symptom limitation [72]. Loads that have typically been applied in these tests include threshold loads [54, 72], or a hybrid between flow resistive loads and threshold loads (tapered flow resistive loading) [73]. Since performance during these

**Table 18.2** Age-specific reference values for maximal respiratory pressure (average peak plateau pressure (95% CI) over 1 s measured from RV and expressed in cmH<sub>2</sub>O)

P <sub>i,max</sub>	18–29	30–39	40–49	50–59	60–69	70–83
Male	128 (116–140)	129 (118–139)	117 (105–129)	108 (99–118)	93 (85–101)	76 (66–86)
Female	97 (89–105)	89 (85–94)	93 (78–107)	80 (75–85)	75 (67–83)	65 (58–73)

Sclausser Pessoa et al. Can Respir J 2014;21(1):43–50




577 tests is influenced by breathing pattern (both  
 578 timing components and inspiratory volumes), it  
 579 has been recommended that these parameters  
 580 should be controlled during tests [72, 74]. Since  
 581 this adds complexity to the procedure, measure-  
 582 ments of inspiratory muscle endurance have  
 583 until recently been regarded as being beyond the  
 584 scope of usual clinical practice [75]. It has been  
 585 argued that these problems might be overcome  
 586 to some extent by registering mouth pressure,  
 587 flow, and inspiratory volumes during the test  
 588 [54]. External work performed during the test  
 589 has been put forward as the most dominant  
 590 determinant of endurance time ( $t_{lim}$ ), regardless  
 591 of the pattern of breathing [54]. With the  
 592 advance of new handheld devices capable of  
 593 continuously registering flow, volume, and pres-  
 594 sure responses, it has become feasible to moni-  
 595 tor breathing pattern and external work of  
 596 breathing during these tests [29, 73]. This has  
 597 created an opportunity to implement well-con-  
 598 trolled endurance tests into the standard clinical  
 599 evaluation of IMT interventions. The protocol  
 600 that will be presented here has recently been  
 601 successfully implemented into a large multi-  
 602 center trial evaluation of respiratory muscle  
 603 function [33]. In short, during this constant load  
 604 test patients are asked to breathe against a sub-  
 605 maximal inspiratory load until task failure due  
 606 to symptom limitation. It has been proposed that  
 607 inspiratory loads should be selected that result  
 608 in a  $t_{lim}$  of less than 7 min at baseline [72, 73]. In  
 609 this way maximal post-intervention test dura-  
 610 tions can be limited to 15 min without important  
 611 ceiling effects [72, 73]. Longer baseline  $t_{lim}$  data  
 612 have previously been shown to result in ceiling  
 613 effects. This lowered effect sizes of a constant  
 614 load test (small to medium effect size of 0.44) in  
 615 comparison to an incremental threshold endur-  
 616 ance test (medium to large effect size of 0.68) in  
 617 response to IMT [76]. Based on these data it  
 618 was concluded that the threshold test might be  
 619 more responsive to IMT interventions. Data  
 620 from a large multicenter RCT however demon-  
 621 strated a large effect size in endurance time  
 622 (0.77) measured with the constant load protocol  
 623 ensuring shorter baseline  $t_{lim}$  (less than 7 min) in  
 624 response to IMT (Fig. 14 [33]).

625 Standardized breathing instructions should be  
 626 provided and post-intervention tests should be  
 627 repeated using an identical load. Improvements  
 628 in  $t_{lim}$  and total external work performed during  
 629 the tests can be recorded as main outcomes of the  
 630 test. Typical changes in breathing parameters  
 631 observed during this test after IMT include [1]  
 632 higher inspiratory flow resulting in shorter inspi-  
 633 ratory time ( $T_i$ ) and [2] increased inspiratory vol-  
 634 ume and work per breath [29]. While a shorter  $T_i$   
 635 could be interpreted as a breathing pattern adap-  
 636 tation that reduces the load on the muscles it also  
 637 reflects the ability of the muscle to perform faster  
 638 contractions against high resistances (i.e.,  
 639 improvements in muscle power). The observed  
 640 increases in inspiratory volume and external  
 641 work (both total and work per breath) are clearly  
 642 not in favor of adopting a breathing pattern that  
 643 would reduce load on the muscles. These changes  
 644 are rather in support of the presence of true  
 645 improvements in inspiratory muscle endurance  
 646 capacity after IMT. They also reflect the stan-  
 647 dardized instructions given to patients on both  
 648 occasions (pre- and post-intervention) to perform  
 649 inspirations as fast, forceful, and as deep as pos-  
 650 sible. The same instructions are provided during  
 651 training sessions. In summary, this constant load  
 652 endurance protocol with standardized breathing  
 653 instructions and registration of breathing param-  
 654 eters offers a feasible technique for implementing  
 655 measures of respiratory muscle endurance into  
 656 clinical practice (Fig. 14 [33]).

### 18.3.4 Training Modalities

657 At this moment, there are few studies available  
 658 comparing different training devices or training  
 659 protocols head to head. Recommendations on  
 660 preferred devices and training protocols for dif-  
 661 ferent purposes are therefore not supported by  
 662 firm evidence. General characteristics along with  
 663 potential benefits and disadvantages of the differ-  
 664 ent methods will be discussed in the following  
 665 sections to formulate recommendations. Three  
 666 different types of loading have been used in most  
 667 respiratory muscle training programs over the  
 668 last decades. These approaches are either primar-



**Fig. 18.3** Improvements in endurance breathing time from incremental ( $P_{thmax}$ ) or constant load ( $t_{lim}$ ) tests in response to high intensity IMT protocols in patients with COPD

670 ily aimed at improving muscle strength (interme- 698  
 671 diate flow/high pressure approach: targeted 699  
 672 resistive loading and threshold loading) or mus- 700  
 673 cle endurance (high flow/low pressure approach: 701  
 674 normocapnic hyperpnea). For all these training 702  
 675 modalities devices are commercially available 703  
 676 that allow to offer controlled home-based train- 704  
 677 ing interventions. A fourth type of loading has 705  
 678 gained popularity in recent years. This so-called 706  
 679 tapered flow resistive loading can be regarded as 707  
 680 a hybrid between threshold loading and targeted 708  
 681 flow resistive loading. More recently developed 709  
 682 electronic devices offer the availability to store 710  
 683 data in an internal memory. These recent devel- 711  
 684 opments might help to facilitate better monitor- 712  
 685 ing and control of home-based training 713  
 686 interventions. A summary of the characteristics 714  
 687 of available methods and devices is provided 715  
 688 in Table 18.3.

### 18.3.5 Targeted Flow Resistive Loading

689 In order to generate a sufficient training resis- 716  
 690 tance of at least 30% of the maximal inspiratory 717  
 691 mouth pressure patients are instructed to generate 718  
 692 high inspiratory flows while breathing through 719  
 693 small holes with varying diameters. The smaller 720  
 694 the diameter, the larger the resistance that needs 721  
 695 to be overcome. Since resistance will be flow 722  
 696 723  
 697 724  
 698 725

dependent devices should be able to register 698  
 inspiratory flow and to provide feedback on the 699  
 achieved flow and pressure response (“targeted 700  
 resistive breathing”). 701

### 18.3.6 Mechanical Threshold Loading

During this method a known and fixed resistance 704  
 generated by a spring loaded valve (isotonic 705  
 threshold load) needs to be overcome before inspi- 706  
 ratory airflow can be generated. After overcoming 707  
 the threshold load an inspiration against this con- 708  
 stant load is possible. This resistance, which 709  
 should also be set at least at 30% of patients  $P_{i,max}$  710  
 is not dependent on the inspiratory flow rate of the 711  
 patient. A feedback-system is therefore less neces- 712  
 sary. A disadvantage of this method (as with any 713  
 isotonic cycle training) is the fact that the inspi- 714  
 ratory muscles will only receive an optimal resis- 715  
 tance (relative to their maximal pressure generating 716  
 capacity) over a short fragment of their full con- 717  
 traction range. As an example let’s assume that the 718  
 $P_{i,max}$  measured at RV is taken as a reference to 719  
 determine training intensity (e.g., training at 50% 720  
 $P_{i,max}$  RV). On initiation of the inspiration at RV 721  
 the training load will be optimal according to this 722  
 target intensity. With increasing lung volume, 723  
 however the constant load will represent an 724  
 increasingly larger fraction of the maximal pres- 725

**Table 18.3** Overview of different training methods and available devices

Training method	Focus	Costs	Feedback-system	Storage training data	Devices
Mechanical threshold loading	Strength and endurance	Low	NA	NA	Threshold IMT <sup>®</sup> ; POWERbreathe Medic <sup>®</sup>
Controlled targeted flow resistive loading	Strength and endurance	High	Visual	Yes	Respift S <sup>®</sup>
Tapered flow resistive loading	Strength and endurance	Moderate	Visual/acoustical	Yes	Powerbreathe (K-Series) <sup>®</sup>
Normocapnic hyperpnea	Endurance	High	Visual/acoustical	Yes	Spirotiger <sup>®</sup>

t3.1  
t3.2  
t3.3  
t3.4  
t3.5  
t3.6  
t3.7  
t3.8  
t3.9  
t3.10  
t3.11  
t3.12

726 sure generating capacity. This will eventually  
727 the ability of the muscle to perform further short-  
728 ening and might limit volume response especially  
729 at higher training intensities (50%  $P_{i,max}$  and more  
730 This has implications for the lengths at which the  
731 respiratory muscles can be stimulated during train-  
732 ing. It is likely to also impact on the perception of  
733 inspiratory effort against a given load [29].

### 734 18.3.7 Tapered Flow Resistive 735 Loading

736 This recently developed type of loading com-  
737 bines the beneficial characteristics of the two  
738 aforementioned loading approaches. After flow-  
739 independently overcoming a threshold load the  
740 resistance is subsequently flow dependently  
741 tapered down during inspiration. This accom-  
742 modates the pressure volume relationship of the  
743 respiratory system and allows full vital capacity  
744 inspirations even at higher training resistances.  
745 This has been shown to result in higher inspira-  
746 tory volumes achieved during training at compa-  
747 rable resistances in comparison with mechanical  
748 threshold loading (Fig. 18.4).

749 The training intensities during an IMT pro-  
750 gram that could be tolerated by patients  
751 comparison with mechanical threshold loading were  
752 higher with this loading approach  
753 comparable perceived respiratory effort scores [29].

#### 754 18.3.7.1 Normocapnic Hyperpnea


755 In contrast to the three previously mentioned  
756 techniques, this type of training does not apply  
757 additional resistances to breathing that need to be

758 overcome. In contrast, by stimulating hyperpnea  
759 at around 60% of the subject's maximal volun-  
760 tary ventilation over a large range of the subject's  
761 vital capacity (deep in- and expirations) for lon-  
762 ger durations (typical training durations of about  
763 30 min) it stimulates the generation of high inspi-  
764 ratory and expiratory flow rates. This approach is  
765 supposed to mainly improve endurance and not  
766 strength of the respiratory muscles. To prevent  
767 hyperventilation resulting in hypocapnia home  
768 training devices have been developed which  
769 ensure normocapnia by partial rebreathing of the  
770 expired air. The execution of the training is tech-  
771 nically challenging and coordination of breathing  
772 has to be practiced thoroughly [76]. It is more-  
773 over challenging to perform for patients with  
774 severe expiratory flow limitation. Based on prin-  
775 ciples of training specificity, this type of training  
776 is not expected to increase maximal pressure gen-  
777 erating capacity. This was confirmed in the latest  
778 meta-analysis in patients with COPD [25].  
779 Moreover the method did also not result in sig-  
780 nificant effects on dyspnea symptoms and func-  
781 tional exercise capacity [25]. Finally, advanced  
782 and rather expensive home training devices pro-  
783 viding both optical and acoustical feedback seem  
784 mandatory to efficiently execute this type of  
785 training in the home setting.

#### 786 18.3.7.2 Training Parameters

787 We recommend the use of either mechanical  
788 threshold loading, targeted flow resistive loading,  
789 or tapered flow resistive loading to train the inspi-  
790 ratory muscles during PR. Based on available  
791 evidence and the complexity of the normocapnic  
792 hyperpnea method, this training modality seems

758/8  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792




**Fig. 18.4** Comparison between two training devices during a typical inhalation against a resistance corresponding to 60% of baseline  $P_{i,max}$  (50 cmH<sub>2</sub>O). *TFRL* tapered flow resistive loading, *MTL* mechanical threshold loading,

*AUC* area under the curve for total external inspiratory work as integrated from mouth pressure (cmH<sub>2</sub>O) and volume (L) signals over time

793 less ideal in this specific setting. Previously many  
 794 programs were applied [79] consisted of 30 min  
 795 of daily strength training at a resistance of at least  
 796 30% of the individuals  $P_{i,max}$ . Recently, shorter,  
 797 high intensity programs have been shown to be  
 798 feasible and effective [29, 77, 78]. These pro-  
 799 grams reduce daily training time to less than  
 800 10 min and use intensities of at least 40%  
 801 (mechanical threshold loading) or even 50%  
 802  $P_{i,max}$  (tapered flow resistive loading). They have  
 803 been studied under both fully and partly super-  
 804 vised conditions (supervision of one training ses-  
 805 sion per week). Since the aim of the intervention  
 806 is to facilitate breathing during periods of  
 807 increased ventilatory needs (i.e., during daily  
 808 physical activities), these shorter training dura-  
 809 tions should be well adapted to the functional  
 810 requirements of patients during daily life. Activity  
 811 monitoring of these patients has revealed that  
 812 most daily activities of patients are carried out in  
 813 bouts of less than 10 min [79, 80]. Training dura-  
 814 tions of 15 or 30 min seem to be less adequate in  
 815 this context. Moreover these high intensity pro-  
 816 grams have been proven to result in large changes  
 817 in  $P_{i,max}$  (Fig. 18.5) and comparable improve-  
 818 ments in respiratory muscle endurance (Fig. 18.6)  
 819 in comparison to programs applying longer train-  
 820 ing durations [29, 77, 78].


821 One training session typically consists of 30  
 822 full vital capacity breaths against resistance and

823 takes an average of 4–5 min to complete. Training  
 824 takes place with the patient seated. Wearing a  
 825 noseclip is not obligated. Patients are permitted  
 826 to lean forward and fix their upper limbs on the  
 827 arms of a chair or a table if desired. It is recom-  
 828 mended that during the rehabilitation period at  
 829 least one training session per week is supervised  
 830 in order to permit the training load to be increased  
 831 and to monitor compliance and progress. In case  
 832 these supervised sessions offer an ideal opportu-  
 833 nity to compare the quality of home-based ses-  
 834 sions with supervised sessions. This will enable  
 835 health care providers to provide patients with  
 836 specific instructions. It is important to stress the  
 837 importance of fast and forceful inspirations and  
 838 the need to achieve the largest possible volume  
 839 response with every breath. This will maximize  
 840 gains in muscle power and increase total work  
 841 performed during training sessions. As with other  
 842 skeletal muscles, improvements in strength are  
 843 likely to be dose-dependent [81]. Progression of  
 844 training intensity by increasing loads over time is  
 845 therefore mandatory. An initial training load  
 846 should be selected equivalent to at least 30% of a  
 847 patient's  $P_{i,max}$ . Loads of less than 30% of  $P_{i,max}$   
 848 are insufficient to induce improvement in inspira-  
 849 tory muscle strength [25, 32]. A typical example  
 850 of progression in training loads during IMT in  
 851 patients with COPD is provided in Fig. 18.6.  
 852



**Fig. 18.5** Comparison of improvements in maximum inspiratory mouth pressure ( $P_{i,max}$ ) in intervention groups in studies applying short, high intensity IMT protocols

**Fig. 18.6** Progression of training intensity expressed as a percentage of baseline  $P_{i,max}$ . *TFRL* tapered flow resistive loading; *MTL* mechanical threshold loading. \* $p < 0.05$  between groups. Dotted lines represent the highest average training intensities reached in the *TFRL* and the *MTL* group, respectively



A symptom-limited approach is recommended to guide the progression of training loads. Selecting loads during which patients describe their respiratory effort at the end of a training session (after 30 breaths) as somewhat hard—that is, between 4–5 on the modified Borg Scale (0–10), seems appropriate. Patients can train at loads corresponding to a higher perceived effort if tolerated. One should aim for the highest tolerable load that still enables full volume expansion during inspiration. On completion of the first training week, patients are often training at loads

equal to approximately 40% of  $P_{i,max}$  with the mechanical threshold loading or 50% with tapered flow resistive loading (Fig. 18.6). The inspiratory load usually needs to be increased rapidly during the first 4 weeks of training, largely because of neural adaptations to training [81, 82]. Weekly adaptation and supervision is therefore strongly recommended during this initial period in order to optimize training response. Thereafter, the rate of increase often slows, and further increments in muscle function are likely to reflect gains resulting from muscular hypertrophy [39].

865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876

877 In the beginning of the program patients should  
 878 be informed about the physiological rationale  
 879 underlying the training (i.e., facilitating exercise  
 880 breathing and reducing perceived breathing dis-  
 881 comfort during endurance exercise training ses-  
 882 sions and daily physical activities). They should  
 883 also be informed about the expected training  
 884 effects and physiological adaptations that take  
 885 place in response to the training. When initiating  
 886 the training the patients should not only receive  
 887 information about the correct technical execution  
 888 of the exercises, but also about hygienic measures  
 889 that should be taken to maintain the equipment.  
 890 Daily cleaning of mouthpieces and breathing  
 891 valves by flushing these parts with tap water and  
 892 regular disinfection of these parts are recom-  
 893 mended to ensure hygienic training circumstances  
 894 and optimal functioning of the breathing devices.

#### 895 **18.4 General Conclusions** 896 **and Recommendations**

897 Until recently well-controlled respiratory muscle  
 898 training interventions were mostly restricted to  
 899 the laboratory setting or specialized hospital  
 900 environment and required extensive supervision  
 901 in order to be performed effectively. Technical  
 902 progress in training equipment and modifications  
 903 in training regimens have however been made in  
 904 recent years. These developments have been  
 905 shown to result in effective and well-controlled  
 906 training programs that can be offered largely  
 907 unsupervised. These recent developments have  
 908 the potential to reduce time investment for both  
 909 health care providers and patients and are  
 910 believed to contribute to facilitate implementa-  
 911 tion of respiratory muscle training interventions  
 912 into PR programs in the coming years. Current  
 913 guidelines acknowledge the potential added  
 914 value of respiratory muscle training within the  
 915 framework of PR mainly for selected patients  
 916 with more pronounced respiratory muscle weak-  
 917 ness. The additional effects on outcomes beyond  
 918 improvements in respiratory muscle function  
 919 when IMT was studied as an add-on intervention  
 920 to general exercise training have mostly been  
 921 reported in this selected group of patients. Better

identifying those patients who are most likely to 922  
 benefit from the intervention will be the most 923  
 important challenge in the years to come. 924

#### References 925

1. Rennard S, Decramer M, Calverley PM, et al. Impact 926  
of COPD in North America and Europe in 2000: sub- 927  
jects' perspective of confronting COPD International 928  
Survey. *Eur Respir J.* 2002;20(4):799–805. 929
2. O'Donnell DE. Hyperinflation, dyspnea, and exercise 930  
intolerance in chronic obstructive pulmonary disease. 931  
*Proc Am Thorac Soc.* 2006;3(2):180–4. 932
3. Manning HL, Schwartzstein RM. Pathophysiology of 933  
dyspnea. *N Engl J Med.* 1995;333(23):1547–53. 934
4. Killian KJ, Jones NL. Respiratory muscles and dys- 935  
pnea. *Clin Chest Med.* 1988;9:237–48. 936
5. Hamilton N, Killian KJ, Summers E, Jones 937  
NL. Muscle strength, symptom intensity, and exercise 938  
capacity in patients with cardiorespiratory disorders. 939  
*Am J Respir Crit Care Med.* 1995;152:2021–31. 940
6. Gosselink R, Troosters T, Decramer M. Peripheral 941  
muscle weakness contributes to exercise limita- 942  
tion in COPD. *Am J Respir Crit Care Med.* 943  
1996;153(3):976–80. 944
7. Laghi F, Tobin MJ. Disorders of the respiratory mus- 945  
cles. *Am J Respir Crit Care Med.* 2003;168(1):10–48. 946
8. Begin P, Grassino A. Inspiratory muscle dysfunction 947  
and chronic hypercapnia in chronic obstructive pulmo- 948  
nary disease. *Am Rev Respir Dis.* 1991;143:905–12. 949
9. Decramer M, Demedts M, Rochette F, Billiet 950  
L. Maximal transrespiratory pressures in obstruc- 951  
tive lung disease. *Bull Eur Physiopathol Respir.* 952  
1980;16(4):479–90. 953
10. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, 954  
Green M, Moxham J. Diaphragm strength in chronic 955  
obstructive pulmonary disease. *Am J Respir Crit Care 956  
Med.* 1996;154(5):1310–7. 957
11. Satta A, Migliori GB, Spanevello A, et al. Fibre 958  
types in skeletal muscles of chronic obstructive 959  
pulmonary disease patients related to respira- 960  
tory function and exercise tolerance. *Eur Respir J.* 961  
1997;10(12):2853–60. 962
12. Levine S, Kaiser L, Leforovich J, Tikunov 963  
B. Cellular adaptations in the diaphragm in chronic 964  
obstructive pulmonary disease. *N Engl J Med.* 965  
1997;337(25):1799–806. 966
13. Testelmans D, Crul T, Maes K, et al. Atrophy and 967  
hypertrophy signalling in the diaphragm of patients 968  
with COPD. *Eur Respir J.* 2010;35(3):549–56. 969
14. De Troyer A, Wilson TA. Effect of acute inflation 970  
on the mechanics of the inspiratory muscles. *J Appl 971  
Physiol* (1985). 2009;107(1):315–23. 972
15. Similowski T, Yan S, Gauthier AP, Macklem PT, 973  
Bellemare F. Contractile properties of the human dia- 974  
phragm during chronic hyperinflation. *N Engl J Med.* 975  
1991;325(13):917–23. 976

- 977 16. Gorman RB, McKenzie DK, Pride NB, Tolman  
978 JF, Gandevia SC. Diaphragm length during tidal  
979 breathing in patients with chronic obstructive pul-  
980 monary disease. *Am J Respir Crit Care Med.*  
981 2002;166(11):1461–9.
- 982 17. Rochester DF. The diaphragm in COPD. Better  
983 than expected, but not good enough. *N Engl J Med.*  
984 1991;325(13):961–2.
- 985 18. Clanton TL, Levine S. Respiratory muscle fiber remodel-  
986 ing in chronic hyperinflation: dysfunction or adapta-  
987 tion? *J Appl Physiol* (1985). 2009;107(1):324–35.
- 988 19. Barreiro E, Bustamante V, Cejudo P, et al. Guidelines  
989 for the evaluation and treatment of muscle dysfunc-  
990 tion in patients with chronic obstructive pulmonary  
991 disease. *Arch Bronconeumol.* 2015;51(8):384–95.
- 992 20. Jolley CJ, Moxham J. Dyspnea intensity: a patient-  
993 reported measure of respiratory drive and disease sever-  
994 ity. *Am J Respir Crit Care Med.* 2016;193(3):236–8.
- 995 21. Aliverti A, Macklem PT. The major limitation to  
996 exercise performance in COPD is inadequate energy  
997 supply to the respiratory and locomotor muscles. *J*  
998 *Appl Physiol* (1985). 2008;105(2):749–51. discussion  
999 755–747
- 1000 22. Debigare R, Maltais F. The major limitation to exer-  
1001 cise performance in COPD is lower limb muscle dys-  
1002 function. *J Appl Physiol* (1985). 2008;105(2):751–3.  
1003 discussion 755–757
- 1004 23. Marchand E, Decramer M. Respiratory muscle func-  
1005 tion and drive in chronic obstructive pulmonary dis-  
1006 ease. *Clin Chest Med.* 2000;21(4):679–92.
- AUT 1007 24. Langer D. Non-pharmacological treatment options  
1008 for hyperinflation. In: Siafakas N, O'Donnell D, edi-  
1009 tors. *Hyperinflation of the lung and its management.*  
1010 p. 90–100.
- 1011 25. Gosselink R, De Vos J, van den Heuvel SP, Segers  
1012 J, Decramer M, Kwakkel G. Impact of inspiratory  
1013 muscle training in patients with COPD: what is the  
1014 evidence? *Eur Respir J.* 2011;37(2):416–25.
- 1015 26. Belman MJ, Shadmehr R. Targeted resistive ventila-  
1016 tory muscle training in chronic obstructive pulmonary  
1017 disease. *J Appl Physiol.* 1988;65(6):2726–35.
- 1018 27. Larson JL, Kim MJ, Sharp JT, Larson DA. Inspiratory  
1019 muscle training with a pressure threshold breathing  
1020 device in patients with chronic obstructive pulmonary  
1021 disease. *Am Rev Respir Dis.* 1988;138(3):689–96.
- 1022 28. Scherer TA, Spengler CM, Owassapian D, Imhof E,  
1023 Boutellier U. Respiratory muscle endurance training  
1024 in chronic obstructive pulmonary disease: impact on  
1025 exercise capacity, dyspnea, and quality of life. *Am J*  
1026 *Respir Crit Care Med.* 2000;162(5):1709–14.
- 1027 29. Langer D, Charususin N, Jacome C, et al. Efficacy  
1028 of a novel method for inspiratory muscle training in  
1029 people with chronic obstructive pulmonary disease.  
1030 *Phys Ther.* 2015;95(9):1264–73.
- 1031 30. Decramer M. Response of the respiratory mus-  
1032 cles to rehabilitation in COPD. *J Appl Physiol.*  
1033 2009;107(3):971–6.
- 1034 31. Lötters F, van TB KG, Gosselink R. Effects of controlled  
1035 inspiratory muscle training in patients with COPD: a  
1036 meta-analysis. *J Eur Respir.* 2002;20(3):570–6.
32. Smith K, Cook D, Guyatt GH, Madhavan J, Oxman  
AD. Respiratory muscle training in chronic airflow  
limitation: a meta-analysis. *Am Rev Respir Dis.*  
1992;145:533–9.
33. Charususin N, Gosselink R, Decramer M, et al.  
Inspiratory muscle training protocol for patients  
with chronic obstructive pulmonary disease (IMTCO  
study): a multicentre randomised controlled trial.  
*BMJ Open.* 2013;3(8):e003101.
34. Spruit MA, Singh SJ, Garvey C, et al. An official  
American Thoracic Society/European Respiratory  
Society statement: key concepts and advances in pul-  
monary rehabilitation. *Am J Respir Crit Care Med.*  
2013;188(8):e13–64.
35. Camillo CA, Osadnik CR, van Remoortel H, Burtin C,  
Janssens W, Troosters T. Effect of “add-on” interven-  
tions on exercise training in individuals with COPD:  
a systematic review. *ERJ Open Res.* 2016;2(1). pii:  
00078-2015.
36. Polkey MI, Moxham J, Green M. The case against  
inspiratory muscle training in COPD. *Eur Respir J.*  
2011;37(2):236–7.
37. Vogelmeier CF, Criner GJ, Martinez FJ, et al.  
Global strategy for the diagnosis, management,  
and prevention of chronic obstructive lung disease  
2017 report: GOLD executive summary. *Eur Respir*  
*J.* 2017;49(3).
38. Gayan-Ramirez G, Rollier H, Vanderhoydonc F,  
Verhoeven G, Gosselink R, Decramer M. Nandrolone  
decanoate does not enhance training effects but  
increases IGF-I mRNA in rat diaphragm. *J Appl*  
*Physiol* (1985). 2000;88(1):26–34.
39. Ramirez-Sarmiento A, Orozco-Levi M, Guell R, et al.  
Inspiratory muscle training in patients with chronic  
obstructive pulmonary disease: structural adaptation  
and physiologic outcomes. *Am J Respir Crit Care*  
*Med.* 2002;166(11):1491–7.
40. Redline S, Gottfried SB, Altose MD. Effects of  
changes in inspiratory muscle strength on the sen-  
sation of respiratory force. *J Appl Physiol* (1985).  
1991;70(1):240–5.
41. Charususin N, Gosselink R, McConnell A, et al.  
Inspiratory muscle training improves breathing pat-  
tern during exercise in COPD patients. *Eur Respir J.*  
2016;47(4):1261–4.
42. Petrovic M, Reiter M, Zipko H, Pohl W, Wanke  
T. Effects of inspiratory muscle training on dynamic  
hyperinflation in patients with COPD. *Int J Chron*  
*Obstruct Pulmon Dis.* 2012;7:797–805.
43. Langer D, Ciavaglia C, Webb K, et al. Inspiratory  
muscle training reduces respiratory neural drive in  
patients with COPD. *Eur Respir J.* 2014;44(Suppl  
58):1912.
44. Perez T, Becquart LA, Stach B, Wallaert B, Tonnel  
AB. Inspiratory muscle strength and endurance in  
steroid-dependent asthma. *Am J Respir Crit Care*  
*Med.* 1996;153:610–5.
45. Stell IM, Polkey MI, Rees PJ, Green M, Moxham  
J. Inspiratory muscle strength in acute asthma. *Chest.*  
2001;120(3):757–64.

- 1097 46. Lavietes MH, Grocela JA, Maniatis T, Potulski F, 1155  
1098 Ritter AB, Sunderam G. Inspiratory muscle strength 1156  
1099 in asthma. *Chest*. 1988;93(5):1043–8. 1157  
1100 47. McKenzie DK, Gandevia SC. Strength and endurance 1158  
1101 of inspiratory, expiratory, and limb muscles in asthma. 1159  
1102 *Am Rev Respir Dis*. 1986;134(5):999–1004. 1160  
1103 48. Silva IS, Fregonezi GA, Dias FA, Ribeiro CT, 1161  
1104 Guerra RO, Ferreira GM. Inspiratory muscle training 1162  
1105 for asthma. *Cochrane Database Syst Rev*. 2013;9: 1163  
1106 CD003792. 1164  
1107 49. Turner LA, Mickleborough TD, McConnell AK, 1165  
1108 Stager JM, Tecklenburg-Lund S, Lindley MR. Effect 1166  
1109 of inspiratory muscle training on exercise tolerance 1167  
1110 in asthmatic individuals. *Med Sci Sports Exerc*. 1168  
1111 2011;43(11):2031–8. 1169  
1112 50. Reid WD, Geddes EL, O'Brien K, Brooks D, 1170  
1113 Crowe J. Effects of inspiratory muscle training in 1171  
1114 cystic fibrosis: a systematic review. *Clin Rehabil*. 1172  
1115 2008;22(10–11):1003–13. 1173  
1116 51. Pinet C, Cassart M, Scillia P, et al. Function and 1174  
1117 bulk of respiratory and limb muscles in patients 1175  
1118 with cystic fibrosis. *Am J Respir Crit Care Med*. 1176  
1119 2003;168(8):989–94. 1177  
1120 52. Ionescu AA, Chatham K, Davies CA, Nixon LS, 1178  
1121 Enright S, Shale DJ. Inspiratory muscle function and 1179  
1122 body composition in cystic fibrosis. *Am J Respir Crit 1180  
1123 Care Med*. 1998;158(4):1271–6. 1181  
1124 53. Santana-Sosa E, Gonzalez-Saiz L, Groeneveld IF, 1182  
1125 et al. Benefits of combining inspiratory muscle with 1183  
1126 'whole muscle' training in children with cystic fibro- 1184  
1127 sis: a randomised controlled trial. *Br J Sports Med*. 1185  
1128 2014;48(20):1513–7. 1186  
1129 54. American Thoracic Society. ERS ATS/ERS Statement 1187  
1130 on respiratory muscle testing. *Am J Respir Crit Care 1188  
1131 Med*. 2002;166(4):518–624. 1189  
1132 55. Enright S, Chatham K, Ionescu AA, Unnithan VB, 1190  
1133 Shale DJ. Inspiratory muscle training improves lung 1191  
1134 function and exercise capacity in adults with cystic 1192  
1135 fibrosis. *Chest*. 2004;126(2):405–11. 1193  
1136 56. de Jong W, van Aalderen WM, Kraan J, Koeter 1194  
1137 GH, van der Schans CP. Inspiratory muscle training 1195  
1138 in patients with cystic fibrosis. *Respir Med*. 1196  
1139 2001;95(1):31–6. 1197  
1140 57. Koulouris NG, Retsou S, Kosmas E, et al. Tidal expi- 1198  
1141 ratory flow limitation, dyspnoea and exercise capacity 1199  
1142 in patients with bilateral bronchiectasis. *Eur Respir J*. 1200  
1143 2003;21(5):743–8. 1201  
1144 58. Moran F, Piper A, Elborn JS, Bradley JM. Respiratory 1202  
1145 muscle pressures in non-CF bronchiectasis: 1203  
1146 repeatability and reliability. *Chron Respir Dis*. 1204  
1147 2010;7(3):165–71. 1205  
1148 59. Rochester CL, Fairburn C, Crouch RH. Pulmonary 1206  
1149 rehabilitation for respiratory disorders other than 1207  
1150 chronic obstructive pulmonary disease. *Clin Chest 1208  
1151 Med*. 2014;35(2):369–89. 1209  
1152 60. Newall C, Stockley RA, Hill SL. Exercise training 1210  
1153 and inspiratory muscle training in patients with bron- 1211  
1154 chiectasis. *Thorax*. 2005;60(11):943–8. 1212
61. Liaw MY, Wang YH, Tsai YC, et al. Inspiratory 1155  
muscle training in bronchiectasis patients: a pro- 1156  
spective randomized controlled study. *Clin Rehabil*. 1157  
2011;25(6):524–36. 1158  
62. de Troyer A, Yernault JC. Inspiratory muscle force in 1159  
normal subjects and patients with interstitial lung dis- 1160  
ease. *Thorax*. 1980;35(2):92–100. 1161  
63. Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common 1162  
mechanisms of dyspnea in chronic interstitial and 1163  
obstructive lung disorders. *Am J Respir Crit Care 1164  
Med*. 2016;193(3):299–309. 1165  
64. O'Donnell DE, Chau LK, Webb KA. Qualitative 1166  
aspects of exertional dyspnea in patients with 1167  
interstitial lung disease. *J Appl Physiol* (1985). 1168  
1998;84(6):2000–9. 1169  
65. Jastrzebski D, Kozielski J, Zebrowska A. Pulmonary 1170  
rehabilitation in patients with idiopathic pulmonary 1171  
fibrosis with inspiratory muscle training. *Pneumonol 1172  
Alergol Pol*. 2008;76(3):131–41. 1173  
66. Vainshelboim B, Oliveira J, Yehoshua L, et al. 1174  
Exercise training-based pulmonary rehabilitation pro- 1175  
gram is clinically beneficial for idiopathic pulmonary 1176  
fibrosis. *Respiration*. 2014;88(5):378–88. 1177  
67. Kenn K, Gloeckl R, Behr J. Pulmonary rehabilita- 1178  
tion in patients with idiopathic pulmonary fibrosis—a 1179  
review. *Respiration*. 2013;86(2):89–99. 1180  
68. Hamnegard CH, Wragg S, Kyroussis D, Aquilina R, 1181  
Moxham J, Green M. Portable measurement of maxi- 1182  
mum mouth pressures. *Eur Respir J*. 1994;7(2):398–401. 1183  
69. Larson JL, Covey MK, Vitalo CA, Alex CG, 1184  
Patel M, Kim MJ. Maximal inspiratory pressure. 1185  
Learning effect and test-retest reliability in patients 1186  
with chronic obstructive pulmonary disease. *Chest*. 1187  
1993;104(2):448–53. 1188  
70. Windisch W, Hennings E, Sorichter S, Hamm H, Crie 1189  
CP. Peak or plateau maximal inspiratory mouth pres- 1190  
sure: which is best? *Eur Respir J*. 2004;23(5):708–13. 1191  
71. Sclauser Pessoa IM, Franco Parreira V, Fregonezi 1192  
GA, Sheel AW, Chung F, Reid WD. Reference values 1193  
for maximal inspiratory pressure: a systematic review. 1194  
*Can Respir J*. 2014;21(1):43–50. 1195  
72. Hill K, Jenkins SC, Philippe DL, Shepherd KL, 1196  
Hillman DR, Eastwood PR. Comparison of incremen- 1197  
tal and constant load tests of inspiratory muscle endur- 1198  
ance in COPD. *Eur Respir J*. 2007;30(3):479–86. 1199  
73. Langer D, Jacome C, Charususin N, et al. Measurement 1200  
validity of an electronic inspiratory loading device 1201  
during a loaded breathing task in patients with 1202  
COPD. *Respir Med*. 2013;107(4):633–5. 1203  
74. Hart N, Hawkins P, Hamnegard CH, Green M, 1204  
Moxham J, Polkey MI. A novel clinical test of 1205  
respiratory muscle endurance. *Eur Respir J*. 1206  
2002;19(2):232–9. 1207  
75. Hill K, Cecins NM, Eastwood PR, Jenkins 1208  
SC. Inspiratory muscle training for patients with 1209  
chronic obstructive pulmonary disease: a practical 1210  
guide for clinicians. *Arch Phys Med Rehabil*. 1211  
2010;91(9):1466–70. 1212



- 1213 76. Göhl O, Walker DJ, Walterspacher S, et al. Respiratory  
1214 muscle training: state of the art. *Pneumologie*.  
1215 2016;70(1):37–48. 1226
- 1216 77. Hill K, Jenkins SC, Philippe DL, et al. High-intensity  
1217 inspiratory muscle training in COPD. *Eur Respir J*.  
1218 2006;27(6):1119–28. 1227
- 1219 78. Sturdy G, Hillman D, Green D, Jenkins S, Cecins N,  
1220 Eastwood P. Feasibility of high-intensity, interval-  
1221 based respiratory muscle training in COPD. *Chest*.  
1222 2003;123(1):142–50. 1228
- 1223 79. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E,  
1224 et al. Physical activity in COPD patients: patterns and  
1225 bouts. *Eur Respir J*. 2013;42(4):993–1002. 1229
80. van Remoortel H, Camillo CA, Langer D, et al. 1230  
Moderate intense physical activity depends on selected 1231  
metabolic equivalent of task (MET) cut-off and type 1232  
of data analysis. *PLoS One*. 2013;8(12):e84365. 1233
81. Kraemer WJ, Fleck SJ, Evans WJ. Strength and 1234  
power training: physiological mechanisms of adapta- 1235  
tion. *Exerc Sport Sci Rev*. 1996;24:363–97. 1236
82. Huang CH, Martin AD, Davenport PW. Effect of 1237  
inspiratory muscle strength training on inspiratory 1238  
motor drive and RREP early peak components. *J Appl*  
1239 *Physiol* (1985). 2003;94(2):462–8. 1240

Uncorrected Proof

# Author Queries

Chapter No.: 18      0003194990

Queries	Details Required	Author's Response
AU1	Please check and confirm if the affiliations and corresponding detail are presented correctly.	
AU2	Please note that part figure labels “a and b” are mentioned in the artwork but not provided in the caption of Fig. 18.1. Kindly check	
AU3	Please check the hierarchy of the section headings and confirm if correct.	
AU4	Please check if the presentation of all the tables are fine.	
AU5	Please note that references have been renumbered both text and reference list to maintain sequential order. Kindly check and correct if necessary.	
AU6	Please note that Figure 18.3 is not cited in the text. Please check that the citation suggested by the copyeditor is in the appropriate place, and correct if necessary.	
AU7	Please check if the edit made in sentence “A disadvantage of this method...” is appropriate.	
AU8	Please check if the edit made in sentence “In contrast, by stimulating hyperpnea...” is appropriate.	
AU9	We have redrawn Figs. 18.1-18.6. This is for your information.	
AU10	Please provide year of publication and publisher name and location for Ref. [24].	